OPM announces its results for the first half of 2023

OPM announces its results for the first half of 2023

Dijon, France, September 19, 2023, at 6:00 pm CEST – Oncodesign Precision Medicine (OPM) (ISIN: FR001400CM63; Mnemonic: ALOPM), a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancer, announces its financial results for the first half of 2023, approved by the Board of Directors on September 19, 2023.